PDCD1 and classic Hodgkin lymphoma: This retrospective, single-center study aimed to evaluate the efficacy and safety of programmed death-1(PD-1)inhibitors, either as monotherapy or in combination with chemotherapy, in the management of relapse/refractory classical Hodgkin's lymphoma(R/R cHL).